Editorial commentary: Ivermectin as a complementary strategy to kill mosquitoes and stop malaria transmission?

Clinical Infectious Diseases

Volumn 60, Issue 3, 2015, Pages 366-368

  Steketee, Richard W ^a   Kuile, Feiko O Ter ^b  

^a PATH   (United States)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

elimination; ivermectin; malaria; mosquito killing

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; INSECTICIDE; IVERMECTIN; PRIMAQUINE;

ANOPHELES; ANOPHELES FUNESTUS; ANOPHELES GAMBIAE; BED NET; HUMAN; INDOOR RESIDUAL SPRAYING; INSECT BITE; INSECTICIDAL ACTIVITY; LIFESPAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MOSQUITO; NONHUMAN; NOTE; PARASITE TRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VECTOR CONTROL; ANIMAL; FEMALE; MALARIA, FALCIPARUM; MALE; TRANSMISSION;

ANIMALS; CULICIDAE; FEMALE; HUMANS; INSECTICIDES; IVERMECTIN; MALARIA, FALCIPARUM; MALE;

EID: 84922424515     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu802     Document Type: Note

References (12)

1. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol 2011; 27: 423-8
2. Chaccour CJ, Kobylinski KC, Bassat Q, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J 2013; 12: 153
3. Ouédraogo AL, Bastiaens GJH, Tiono AB, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis 2015; 60: 357-65
4. Mectizan donation program: annual highlights. The accomplishments of the Mectizan donation program in its 26th year, 2013. Available at: http://www.mectizan. org/sites/www.mectizan.org/files/attachments/resources/AH2013WEB-0.pdf. Accessed 17 October 2014
5. Sylla M, Kobylinski KC, Gray M, et al. Mass drug administration of ivermectin in southeastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J 2010; 9: 365
6. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis 2014; doi: 10.1093/infdis/jiu351
7. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis 2010; 202: 113-6
8. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg 1999; 93: 189-94
9. Fobi G, Gardon J, Kamgno J, et al. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Trans R Soc Trop Med Hyg 2005; 99: 279-89
10. Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or threemonthly. Trans R Soc Trop Med Hyg 2004; 98: 496-504
11. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42: 1122-33
12. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012; 11: 418